Our news


Additional Series B funding announcement

We are delighted to announce that additional Series B funding has been agreed, with the members of Italian Angels for Growth and Club degli…


Neophore appoints Stephen Over as Chief Financial Officer

We are delighted to announce the appointment of Stephen Over as the Company's Chief Financial Officer and new member of the Executive team. Stephen…


NeoPhore Announces Scientific Founder Dr Alberto Bardelli Awarded €2.5 million European Research Council (ERC) Advanced Grant

22 April, Cambridge, UK – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced that its scientific founder, Dr A…


NeoPhore Announces £15.2m Financing to Advance DNA Mismatch Repair Pipeline

Round led by Claris Ventures with 2Invest, 3B Future Health Fund and Astellas Venture Management 9 March 2021, Cambridge, UK – NeoPhore Limited, a s…

Other news


BioCentury's Emerging Company Profile

CEO Jeff Roix spoke to BioCentury about how NeoPhore Ltd is developing small molecules to inhibit DNA mismatch repair (MMR) and create a pool of…


NeoPhore Enters Immuno-Oncology Fray With DNA-Repair Technology

Scrip Emerging company profile: UK-based NeoPhore, founded in 2017, is developing novel cancer therapies based on DNA-repair technology. The company…